Breadcrumb

[A15-24] Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2015-06-30 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 239 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A17-32] Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A16-62] Ceritinib (lung cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2015-10-01 Extract of dossier assessment 239 kBPDFdownload file
2015-10-01 Dossier assessment (German version) 506 kBPDFdownload file


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment) [PDF, 239 kB]

Federal Joint Committee (G-BA)

2015-12-17 G-BA decision was published.

G-BA documents on this decision

Press releases

2015-10-01 Ceritinib in advanced lung cancer: no hint of added benefit



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close